Long-Term Outcomes of Boston Type I Keratoprosthesis are pos
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to evaluate the long-term outcomes, anatomical retention and complications of Boston type I keratoprosthesis (KPro).

A retrospective chart review of implantations performed was conducted. Risk factors for anatomical retention and functional success were analyzed. The incidences of infections with and without antimicrobial medications were compared.

Results:
--27 eyes of 26 patients were recruited. The most common indication for KPro surgery was failed penetrating keratoplasties (PKP; 22 eyes, 81.5%).

--All patients had preoperative best-corrected visual acuity (BCVA) worse than 3/60. Over the mean follow-up of 83.4 ± 28.4 months, 15 eyes demonstrated improved BCVA.

--The anatomical retention rate was 88.9%, and the functional success rate was 44.4%.

--Eyes with ocular surface disease (OSD) had significantly more complications than those without OSD.

--The most common complications were retroprosthetic membrane formation (15 eyes, 55.6%) and infection (13 eyes, 48.1%).

--Infectious keratitis was primarily caused by gram-positive bacteria, while endophthalmitis was chiefly caused by fungal infection.

--The infection incidence was significantly lower in eyes using topical 0.1% amphotericin B and 5% povidone iodine.

Boston Type I KPro can ultimately be an alternative treatment for patients with traditional PKP failure with good retention rates and aesthetic results, especially with adequate patient selection and prevention of complications. The optional effective regimes for infection prevention in particular tropical countries may be standard prophylactic antibiotics with topical 0.1 % amphotericin B and 5 % povidone iodine.

Source: https://www.sciencedirect.com/science/article/abs/pii/S0002939421003159?dgcid=rss_sd_all
Like
Comment
Share